Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Acumen Pharmaceuticals announces today the termination by Merck Sharp & Dohme Corp., (formerly Merck & Co., Inc.) of a 2003 agreement, amended in 2006, under which Acumen granted Merck exclusive worldwide rights to develop and commercialize anti-ADDL antibody therapeutics and diagnostics for Alzheimer's disease.

Merck's decision to discontinue this anti-ADDL Alzheimer's program and terminate the Merck-Acumen license agreement was based on internal strategic priorities. Under the termination provisions of the agreement, Acumen regains rights licensed to Merck, and also receives certain rights to patent applications and know how generated during the term of the Agreement. Anti-ADDL antibodies have high selectivity for soluble amyloid beta oligomers versus monomeric amyloid beta peptides or insoluble amyloid beta aggregates. Acumen believes this selectivity will favorably differentiate Acumen anti- ADDL immunotherapies compared to amyloid beta immunotherapies currently in late stage clinical testing.

"Acumen is very pleased to regain worldwide rights for the development and commercialization of anti-ADDL antibody therapeutics and diagnostics," stated Grant Krafft, Acumen's Chairman and Chief Science Adviser.

Acumen's Board of Directors also announces the appointment of Franz Hefti, Ph.D. as Acumen's President and CEO. Dr. Hefti has served as a Director of Acumen since 2008 and has a distinguished record in drug development and biotechnology ventures. Dr. Hefti served as Chief Science Officer for Avid Radiopharmaceuticals, which Eli Lilly & Co. acquired in 2010 for its Alzheimer's imaging product, Amyvid™. Prior to Avid, Dr. Hefti was Executive Vice President of Drug Development for Rinat Neuroscience Corporation where he led preclinical and clinical drug development efforts for three antibody drug candidates. The success of these programs led to Pfizer's 2006 acquisition of Rinat.
'/>"/>

SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Receives NHPD/Health Canada Authorization to Begin a Study on, ... (Immunocal(R)) in, Combination with Physical Exercise on ... Levels in Elderly Persons: A Randomized, Double-Blind ... Inc. (TSX-V: IMM) announced today that the Natural Health Products ...
... the ninth consecutive year, internationally acclaimed celebrities will come ... http://starkeyhearingfoundation.org ), , the global leader in ... its mission of providing hearing instruments to underprivileged children ... will gather for the Foundation,s annual "So the World ...
... 7 OncoMed Pharmaceuticals, Inc., a clinical-stage company developing ... announced the appointment of Sunil Patel to the position ... new position, Mr. Patel will have primary responsibility for ... OncoMed,s President and Chief Executive Officer. , , ...
Cached Biology Technology:2009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process 22009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process 3Celebrities to Gather to Support the Ninth Annual Starkey Hearing Foundation 'So the World May Hear' Awards Gala 2Celebrities to Gather to Support the Ninth Annual Starkey Hearing Foundation 'So the World May Hear' Awards Gala 3OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development 2
(Date:4/24/2014)... home from Iraq and Afghanistan, post-traumatic stress disorder (PTSD) ... and the culture at-large. Estimates indicate that as many ... Afghanistan suffer from PTSD. New research from the University ... on how PTSD is linked to other diseases in ... has implications beyond the impact of the psychiatric disorder ...
(Date:4/24/2014)... A common plant puts out a welcome mat to bacteria ... mix. , The study published this week in the ... targets during the battle between microbe and host that researchers ... the humble and oft-studied plant Arabidopsis puts out ... It,s as if a hostile army were unknowingly passing by ...
(Date:4/23/2014)... The greater prevalence of asthma, allergies and other chronic ... be due in part to their reduced exposure to ... a new scientific paper. , The article, published in ... that people living in urban centers who have less ... have chronic inflammation, a condition caused by immune system ...
Breaking Biology News(10 mins):New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3
... into young adults, increasing time constraints due to school or work ... a study published in the January 2009 issue of the ... young adults enjoy and value time spent eating with others, 35% ... down and eat a meal. They further noted that "eating on ...
... 2009) - This month,s issue of Cold ... articles detailing experimental methods for the analysis of molecular ... proteins. Homologous recombination is an important mechanism for ... a Displacement Loop, or "D-loop," is formed as the ...
... Calif., January 5, 2009-- Scientists at Burnham Institute ... of the interactions between proteins that form the ... which is responsible for triggering apoptosis (programmed cell ... Ph.D., and colleagues, published online on Dec. 31 ...
Cached Biology News:Young adults need to make more time for healthy meals 2Methods for studying DNA repair and protein modification are featured in CSH Protocols 2Burnham researchers discover 'on switch' for cell death signaling mechanism 2
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
E2F-5...
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Biology Products: